THE EFFECTS OF CLINICAL, LABORATORY, and ANGIOGRAPHIC FACTORS ON STENT THROMBOSIS and MAJOR ADVERSE CARDIAC EVENTS IN PACLITAXEL ELUTING STENTS
Abstract
Background: Drug-eluting stents (DES) have higher marked efficacy and lower revascularization requirements compared to bare metal stents (BMS). We aimed to determine the mid-term outcomes of patients implanted with first-generation DES “paclitaxel-eluting stents” (PES).
Methods: Patients with at least 1 PES implanted in our cardiology clinic were received in the non-randomized group. Inclusion criteria were all patients undergoing percutaneous coronary intervention and PES implantation. The mean follow-up time was 35.14 + 13.4 months.
Results: A total of 302 patients (401 lesions and 337 PES) were enrolled in the study. The mean age was 61.86 + 10.27 years. Major adverse cardiac and cerebrovascular events (MACE) occurred at 17.9%, and the stent thrombosis rate was 4%. Independent predictors of stent thrombosis were serum creatinine levels [OR 1.59; 95% CI, 1.03-2.46, p=0.03] and mean platelet volume [OR 1.59; 95% CI, 1.03–2.46, p= 0.03]. Also, poor functional capacity [OR 2.46: 95% CI, 1.42- 4.26, p<0.001] and positive ischemia test [OR 3.43: 95% CI, (1.73-6.82), p<0.001] were predictors of MACE's.
Conclusions: We have demonstrated that PES is safe and effective in the mid-term for use in coronary artery disease.
References
1. Ahadi F, Azadi M, Biglari M, Bodaghi M, Khaleghian A. Evaluation of coronary stents: A review of types, materials, processing techniques, design, and problems. Heliyon. 2023;9(2):e13575. doi: 10.1016/j.heliyon.2023.e13575.
2. Chhabra L, Zain MA, Siddiqui WJ. Coronary Stents. 2023 Jan 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan
3. Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36(2):158-68. doi: 10.1007/s12928-021-00754-x.
4. Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini GG, Polimeni A. Stent thrombosis and restenosis with contemporary drug-eluting stents: predictors and current evidence. J Clin Med. 2023;12(3):1238. doi: 10.3390/jcm12031238.
5. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7– 8, 2006.Circulation. 2007;115:2352–7. doi: 10.1161/CIRCULATIONAHA.107.688416.
6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393.
7. Collet J.-P., Thiele H. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation-Dual versus triple antithrombotic therapy. Eur. Heart J.Eur Heart J. 2021;42(20):2020-1. doi: 10.1093/eurheartj/ehaa909.
8. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241. doi: 10.1186/s12874-021-01440-5.
9. Sousa A, Costa R, Moreira AC, Cano M, Maldonado G, Costa RA, et al. Long-term clinical outcomes of the drug-eluting stents in the real world (DESIRE) Registry. J Interven Cardiol. 2008;21(4):307– 14.doi: 10.1111/j.1540-8183.2008.00379.x.
10. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, et al. Long-term safety and efficacy of drug-eluting stents two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry. Circulation. 2007;115(25):3181-8. doi: 10.1161/CIRCULATIONAHA.106.667592.
11. Lasala JM, Cox DA, Dobies D,Muhlestein JB, Katopodis JN, Revtyak G,et al. Usage patterns and 2-year outcomes with the TAXUS Express Stent: Results of the US ARRIVE 1 Registry. Catheter Cardiovasc Interv. 2008;72(4):433–45.doi: 10.1002/ccd.21618.
12. Yamaji K, Räber L, Zanchin T, Spitzer E, Zanchin C, Pilgrim T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37(45):3386-95.doi: 10.1093/eurheartj/ehw343.
13. Galløe AM, Kelbæk H, Thuesen L, Hansen HS, Ravkilde J, Hansen PR, et al. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary ctents. J Am Coll Cardiol. 2017;69(6):616-24. doi: 10.1016/j.jacc.2016.11.055.
14. Räber L, Wohlwend L, Wigger M,Togni M, Wandel S, Wenaweser P,et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123(24):2819-28. doi:10.1161/CIRCULATIONAHA.110.004762.
15. Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP,et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. JACC Cardiovasc Interv. 2010;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.
16. Park H, Kang DY, Kim SO, Lee J, Kim JH, Hyun J et al. Ten-year outcomes of early generation sirolimus- versus paclitaxel-eluting stents in patients with left main coronary artery disease. Catheter Cardiovasc Interv. 2021;98(5):E705-14. doi: 10.1002/ccd.29930.
17. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023; 44(15):1343-57. doi: 10.1093/eurheartj/ehad026.
18. Thuijs DJFM, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394(10206):1325-34. doi: 10.1016/S0140-6736(19)31997-X.
19. S. Cook, E. Ladich, G. Nakazawa, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120(5):391-9. doi: 10.1161/CIRCULATIONAHA.109.854398.
20. De la Torre-Herna´ndez JM, Alfonso F, Herna´ndez F, Elizaga J, Sanmartin M, Pinar E,et al. Drug-eluting stent thrombosis: Results from the multicenter Spanish Registry ESTROFA. J Am Coll Cardiol. 2008;51(10):986–90.doi: 10.1016/j.jacc.2007.10.057.
21. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER Registry. Circulation. 2006;113(24):2803-09.doi: 10.1161/CIRCULATIONAHA.106.618066
22. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584–91.doi: 10.1016/j.jacc.2006.10.026.
23. Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol. 2009;104(10):1357-61. doi: 10.1016/j.amjcard.2009.07.002.
24. Slottow TLP, Steinberg DH, Roy PK, Buch AN, Okabe T, Xue Z,et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008;102(3):298–03. doi: 10.1016/j.amjcard.2008.03.055.
25. Gyöngyösi M, Christ G, Lang I, Kreiner G, Sochor H, Probst P, et al. AUTAX Investigators. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study JACC Cardiovasc Interv. 2009;2(8):718-27.doi: 10.1016/j.jcin.2009.05.019.
26. Waksman R, Kirtane AJ, Torguson R, Cohen DJ, Ryan T, Räber L, et al. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). JACC Cardiovasc Interv. 2014;7(10):1093-102. doi: 10.1016/j.jcin.2014.04.017
27. Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(5):e2651.
doi: 10.1097/MD.0000000000002651.
28. Sleiman E, Tabet R, Karam B, Ayad D, Royzman R. Extremely late in-stent thrombosis 12 years after implantation of a drug-eluting stent. Cureus. 2020;12(7):e9053. doi: 10.7759/cureus.9053..
29. Barbato E, Mehilli J, Sibbing D, Siontis GCM, Collet JP, Thiele H,et al. ESC Scientific Document Group. Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1368-78.doi: 10.1093/eurheartj/ehaa601.
Copyright (c) 2023 Sanamed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Sanamed is published under an Open Access license. All its content is available free of charge. Users can read, download, copy, distribute, print, search the full text of articles, as well as establish HTML links to them, without having to seek the consent of the author or publisher.
The right to use content without consent does not release the users from the obligation to give the credit to the journal and its content in a manner described under CC BY.